Hensing TA - Search Results

1

Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial.

Socinski MA, Morris DE, Halle JS, Moore DT, Hensing TA, Limentani SA, Fraser R, Tynan M, Mears A, Rivera MP, Detterbeck FC, Rosenman JG. Socinski MA, et al. Among authors: hensing ta. J Clin Oncol. 2004 Nov 1;22(21):4341-50. doi: 10.1200/JCO.2004.03.022. J Clin Oncol. 2004. PMID: 15514375 Clinical Trial.

2

Combined-modality therapy in the nonsurgical management of unresectable stage III non-small cell lung cancer.

Hensing TA, Socinski MA. Hensing TA, et al. Curr Opin Pulm Med. 1999 Jul;5(4):194-200. doi: 10.1097/00063198-199907000-00003. Curr Opin Pulm Med. 1999. PMID: 10407686 Review.

3

The role of induction therapy in the management of resectable non-small cell lung cancer.

Hensing TA, Detterbeck F, Socinski MA. Hensing TA, et al. Cancer Control. 2000 Jan-Feb;7(1):45-55. doi: 10.1177/107327480000700104. Cancer Control. 2000. PMID: 10740660 Free article. Review.

4

Brain metastases.

Ewend MG, Carey LA, Morris DE, Harvey RD, Hensing TA. Ewend MG, et al. Among authors: hensing ta. Curr Treat Options Oncol. 2001 Dec;2(6):537-47. doi: 10.1007/s11864-001-0075-8. Curr Treat Options Oncol. 2001. PMID: 12057099 Review.

5

The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel.

Hensing TA, Peterman AH, Schell MJ, Lee JH, Socinski MA. Hensing TA, et al. Cancer. 2003 Aug 15;98(4):779-88. doi: 10.1002/cncr.11548. Cancer. 2003. PMID: 12910523 Free article. Clinical Trial.

6

Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer.

Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, Hensing TA, Socinski MA. Fried DB, et al. Among authors: hensing ta. J Clin Oncol. 2004 Dec 1;22(23):4837-45. doi: 10.1200/JCO.2004.01.178. J Clin Oncol. 2004. PMID: 15570087 Review.

7

Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer.

Hensing TA, Schell MJ, Lee JH, Socinski MA. Hensing TA, et al. Lung Cancer. 2005 Feb;47(2):253-9. doi: 10.1016/j.lungcan.2004.07.040. Lung Cancer. 2005. PMID: 15639724 Clinical Trial.

8

A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer.

Gillenwater HH, Stinchcombe TE, Qaqish BF, Tyann M, Hensing TA, Socinski MA. Gillenwater HH, et al. Among authors: hensing ta. Lung Cancer. 2005 Mar;47(3):413-9. doi: 10.1016/j.lungcan.2004.08.009. Lung Cancer. 2005. PMID: 15713525 Clinical Trial.

9

Duration of therapy in advanced, metastatic non-small-cell lung cancer.

Socinski MA, Baggstrom MQ, Hensing TA. Socinski MA, et al. Among authors: hensing ta. Clin Adv Hematol Oncol. 2003 Jan;1(1):33-8. Clin Adv Hematol Oncol. 2003. PMID: 16227958

10

A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer.

Socinski MA, Ivanova A, Bakri K, Wall J, Baggstrom MQ, Hensing TA, Mears A, Tynan M, Beaumont J, Peterman AH, Niell HB. Socinski MA, et al. Among authors: hensing ta. Ann Oncol. 2006 Jan;17(1):104-9. doi: 10.1093/annonc/mdj016. Epub 2005 Oct 25. Ann Oncol. 2006. PMID: 16249215 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

63 results

Search Page

Filters